Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:00:32.138Z.
Calculation as of: 2026-10-06T16:00:32.138Z.
Quote observation: 2026-10-06T16:00:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 031dd4b10f0f14a16e9eaccfeacbabe2220a5c10b94ef049f803708fa703ac6d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$289.63M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.97M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.29M
EV/EBIT Ratio
N/A
TTM Avg
15.89x
3Y Avg
15.15x
5Y Avg
15.15x
Market Cap
$300.36M
EV/EBIT Ratio
N/A
TTM Avg
23.87x
3Y Avg
23.87x
5Y Avg
23.87x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $288.40M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $288.98M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $281.97M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.83M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.12M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A | 15.89x | 15.15x | 15.15x |
| Fate Therapeutics, Inc. (FATE)vs › | $278.55M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.36M | N/A | 23.87x | 23.87x | 23.87x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
